Why Buy Modafinil

With over 1700 clinical trials, Modafinil is still considered the safest smart drug available today!

Programmed TV, YouTube channels, and articles focused on choosing providers’ demographics.

Fox News for Republicans and MSNBC for the Democrats, for example.

The public wants a nonbiased source that tells the truth without a slant, including the good, bad, and ugly.

I aim to provide the best information about the practical use and risks of taking Modafinil.

The following quote comes from a ‘study’ on Modafinil in 2012.

Conclusion
Anyone wishing to work late, stay awake, enhance their cognitive reactions, or brighten their moods can use modafinil.

Key Takeaways

1. Safety and Clinical Trials: Modafinil is a safe, smart drug backed by over 1700 clinical trials​​.
2. FDA Approval and Usage since 2003: The drug has been in use since 2003 and received FDA approval in 2006​​.
3. Off-label Benefits: Besides its primary uses, Modafinil is known for mood-brightening, memory enhancement, and combating fatigue due to various conditions​​.
4. Low Addiction Probability: Modafinil has a low probability of addiction, but excessive use can lead to sleeplessness​​.

Practical Use of Taking Modafinil

Once on the market, Modafinil became known for its off-label benefits;

• Mood-brightening,
• Memory-enhancing,
• and its waking effect.

Modafinil’s Use also widened to include the treatment of;

• Memory loss due to dementia,
• ADHD,
• Jet lag,
• and fatigue caused by extended work hours or illnesses.

Also, Modafinil can be used by anyone who wishes to work late and concentrate for a long time.

High school students, examinees for new career development, and athletes have flocked to Modafinil for the above benefits.

I’m a truck driver, so being awake and alert is part of my job. And that’s so easy with Modafinil. Herman. V. ⭐⭐⭐⭐⭐

Risk of taking Modafinil

Modafinil has been available for Use since 2003 and was approved by the FDA in 2006. Over that time, Modafinil has undergone over 1700 clinical trials.

Modafinil is a well-tolerated drug with a low probability of addiction. However, taking Modafinil too much could result in sleeplessness.

And sleep is the most important thing we can do for ourselves to create a healthy mind and body.

Staying hydrated when using Modafinil is essential, as headaches are the most common side effect. Researchers believe this may be caused by Modafinil dehydrating the brain.

More research needs to be conducted in this area.

Finding The Right Modafinil Dose.

Like most medications, Modafinil affects people differently. Testing Modalert & Modvigil is the only way to find the correct Modafinil dose!

Week 1, Days 1 & 2.

• Modafinil Dose.
  • 1 Modvigil, in the morning,
• Results.
  • No rush or sweating as I get with Modalert. I felt regular but more energetic and focused & my mood was elevated.
  • I got to sleep a little later than usual. Other than that, a good result.

Day 3.

• Modafinil Dose,
  • 2 Modvigil @ the same time.
• Results.
  • That had a negative effect; I felt slightly confused and had a slight headache 8 hours later.
  • Felt a bit like I was recovering from a hangover, a sort of brain numbness.
  • It was not a very productive day. I felt some change in mood. But the effects were adverse enough that I have never tried that again.

Day 4.

• Modafinil Dose,
  • Day off.
• Results.
  •  Felt fine; the effects of the day before had gone. However, I did feel like I had more energy.

Days 5 & 6.

• Modafinil Dose,
  • 1 Modvigil at 5 am & another Modvigil 2 hours later.
• Results.
  • That was perfect. I was on point both days and did not miss a beat.
  • “I still do that once or twice a month to this day. When I need to finish a lot of work”.
  • I slept fine that night.

Day 7.

• Modafinil Dose,
  • Day off
• Results.
  • Felt like I was still feeling the effects from yesterday—a very productive day.
  • There is no rush or uncomfortable feeling, just the focus & alertness all day.

I like the feeling I get when I take Modafinil; it is better than coffee!

J.Jackson ⭐⭐⭐⭐⭐

Week 2, Day 1

• Modafinil Dose,
  • 1  Modalert,
• Results.
  • That’s stronger than the Modvigil. Very similar to the Modalert. Sweating and a rush with the onset.
  • I felt on edge; my mind was too busy to focus. I felt like getting up and doing something.
  • A very productive day. However, I talked a lot more than usual.
  • I went to the gym after work for an intense workout.
  • Not bad, but it’s not what I want at work. I had a slight headache that night; I slept fine.

Day 2

• Modafinil Dose,
  • 1/2 Modalert.
• Results
  • Much better and similar to Modvigil. I’m still a little bit on edge, but nothing like yesterday.
  • I took the other half at 11 am. No headache that night.
  • Slept fine. It was a very productive day.

Day 3

• Modafinil Dose,
  • 1 Modvigil at 5 am and 1 Modalert 2 hours later. After the adverse effects. With double-dosing Modvigil, I decided against doing the same with the Modalert.
• Results.
  • I was rocked by 8 am. I felt like I was on amphetamines, had a dry mouth, was slightly sweating, and couldn’t stop talking to anyone who would listen.
  • Probably not the best at work, but on the weekend?
  • Very productive day.

Day 4 & the end of the trial

• Modafinil Dose,
  • With the confidence of day three, I went for 2 Modalert, 2 hours apart.
• Results.
  • Similar results were obtained on day 3; it was not the best day for working, but it was fun.
  • I had trouble sleeping that night.

Finding The Right Modafinil Dose, Conclusion

After some trial and error, I finally found my correct Modafinil Dosage.

My perfect Modafinil dose is one pill daily and two pills two hours apart on a busy day.

I’m a truck driver, so being awake and alert is part of my job. And that’s so easy with Modafinil. Herman. V. ⭐⭐⭐⭐⭐

FAQs

1. What are the primary benefits of Modafinil?
   • Modafinil offers mood-brightening, memory-enhancing effects and helps in staying awake​​.
2. Is Modafinil safe to use?
   • It is considered safe, with over 1700 clinical trials verifying its safety​​.
3. When did the FDA approve Modafinil?
   • Modafinil was approved by the FDA in 2006​​.
4. Can Modafinil lead to addiction?
   • It has a low probability of addiction, though misuse can result in negative effects like sleeplessness​​.
5. What are the side effects of Modafinil?
   • The most common side effect is headaches, potentially due to dehydration caused by the drug​​.

Reference

• https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3286657/
• Happe S. Excessive daytime sleepiness and sleep disturbances in patients with neurological diseases: epidemiology and management. Drugs. 2003;63(24):2725–2737. [PubMed] [Google Scholar]
• Kim D. Studies on neuroimmune regulation of the psychoactive drug, Modafinil; Proceedings of the Korea Institute of Military Science and Technology; June 2-3, 2011; Jeju. Daejeon: Korea
• Institute of Military Science and Technology; 2011. pp. 1518–1521. [Google Scholar]
• Mignot E. An update on the pharmacotherapy of excessive daytime sleepiness and cataplexy. Sleep Med Rev. 2004;8(5):333–338. [PubMed] [Google Scholar]
• Robertson P, Jr, Hellriegel ET. Clinical pharmacokinetic profile of Modafinil. Clin Pharmacokinet. 2003;42(2):123–137. [PubMed] [Google Scholar]
• Harsh JR, Hayduk R, Rosenberg R, Wesnes KA, Walsh JK, Arora S, et al. The efficacy and safety of armodafinil as a treatment for adults with excessive sleepiness associated with Narcolepsy. Curr Med Res Opin. 2006;22(4):761–774. [PubMed] [Google Scholar]
• Scholl JL, Feng N, Watt MJ, Renner KJ, Forster GL. Individual differences in amphetamine sensitization, behavior, and central monoamines. Physiol Behav. 2009;96(3):493–504. [PMC free article] [PubMed] [Google Scholar]
• Jasinski DR. An evaluation of the abuse potential of Modamodafinilng methylphenidate as a reference. J Psychopharmacol. 2000;14(1):53–60. [PubMed] [Google Scholar]
• Caldwell JA, Mallis MM, Caldwell JL, Paul MA, Miller JC, Neri DF. Fatigue countermeasures in aviation. Aviat Space Environ Med. 2009;80(1):29–59. [PubMed] [Google Scholar]
• Breitbart W, Alici Y. Pharmacologic treatment options for cancer-related fatigue: current state of clinical research. Clin J Oncol Nurs. 2008;12(5 Suppl):27–36. [PubMed] [Google Scholar]
• Blackhall L, Petroni G, Shu J, Baum L, Farace E. A pilot study evaluated the safety and efficacy of Modafinil for cancer-related fatigue. J Palliat Med. 2009;12(5):433–439. [PubMed] [Google Scholar]
• Menza MA, Kaufman KR, Castellanos A. Modafinil augmentation of antidepressant treatment in depression. J Clin Psychiatry. 2000;61(5):378–381. [PubMed] [Google Scholar]
• Gill M, Haerich P, Westcott K, Godenick KL, Tucker JA. Cognitive performance following Modafinil versus placebo in sleep-deprived emergency physicians: a double-blind, randomized crossover study. Acad Emerg Med. 2006;13(2):158–165. [PubMed] [Google Scholar]
• Caldwell JA, Caldwell JL, Crowley JS, Jones HD. Sustaining helicopter pilot performance with Dexedrine during periods of sleep deprivation. Aviat Space Environ Med. 1995;66(10):930–937. [PubMed] [Google Scholar]
• Huck NO, McBride SA, Kendall AP, Grugle NL, Killgore WD. The effects of Modafinil, caffeine, and dextroamphetamine on judgments of simple versus complex emotional expressions following sleep deprivation. Int J Neurosci. 2008;118(4):487–502. [PubMed] [Google Scholar]
• Lorton D, Lubahn CL, Estus C, Millar BA, Carter JL, Wood CA, et al. Bidirectional communication between the brain and the immune system: implications for physiological sleep and disorders. Neuroimmunomodulation. 2006;13(5-6):357–374. [PubMed] [Google Scholar]
• Everson CA, Toth LA. Systemic bacterial invasion induced by sleep deprivation. Am J Physiol Regul Integr Comp Physiol. 2000;278(4): R905–R916. [PubMed] [Google Scholar]
• Fava M. Pharmacological approaches to the treatment of residual symptoms. J Psychopharmacol. 2006;20(3 Suppl):29–34. [PubMed] [Google Scholar]
• Houlihan DJ. Psychostimulant treatment of combat-related posttraumatic stress disorder. J Psychopharmacol. 2011;25(11):1568–1572. [PubMed] [Google Scholar]
• Caldwell JA, Caldwell JL. Fatigue in military aviation: an overview of US military-approved pharmacological countermeasures. Aviat Space Environ Med. 2005;76(7 Suppl): C39–C51. [PubMed] [Google Scholar]
• Robertson SD, Matthies HJ, Galli A. A closer look at amphetamine-induced reverse transport and trafficking of the dopamine and norepinephrine transporters. Mol Neurobiol. 2009;39(2):73–80. [PMC free article] [PubMed] [Google Scholar]
• Del Arco A, Gonzalez-Mora JL, Armas VR, Mora F. Amphetamine increases the extracellular concentration of glutamate in the striatum of the awake rat: involvement of high-affinity transporter mechanisms. Neuropharmacology. 1999;38(7):943–954. [PubMed] [Google Scholar]
•  Knapp PH. Amphetamine and addiction. J Nerv Ment Dis. 1952;115(5):406–432. [PubMed] [Google Scholar]
•  
• Killgore WD, Rupp TL, Grugle NL, Reichardt RM, Lipizzi EL, Balkin TJ. Effects of dextroamphetamine, caffeine, and Modafinil on psychomotor vigilance test performance after 44 h of continuous wakefulness. J Sleep Res. 2008;17(3):309–321. [PubMed] [Google Scholar]
• Adler LA. Pharmacotherapy for adult ADHD. J Clin Psychiatry. 2009;70(5):e12. [PubMed] [Google Scholar]
• Leith NJ, Kuczenski R. Chronic amphetamine: tolerance and reverse tolerance reflect different behavioral actions of the drug. Pharmacol Biochem Behav. 1981;15(3):399–404. [PubMed] [Google Scholar]
• Ortweiler W, Simon HU, Splinter FK, Peiker G, Siegert C, Traeger A. Determination of caffeine and metamizole elimination in pregnancy and after delivery as an in vivo method for characterization of various cytochrome p-450 dependent biotransformation reactions. Biomed Biochim Acta. 1985;44(7-8):1189–1199. (German) [PubMed] [Google Scholar]
• Daly JW, Jacobson KA, Ukena D. Adenosine receptors: development of selective agonists and antagonists. Prog Clin Biol Res. 1987;230:41–63. [PubMed] [Google Scholar]
• Fisone G, Borgkvist A, Usiello A. Caffeine as a psychomotor stimulant: mechanism of action. Cell Mol Life Sci. 2004;61(7-8):857–872. [PubMed] [Google Scholar]
• Childs E, de Wit H. Enhanced mood and psychomotor performance by a caffeine-containing energy capsule in fatigued individuals. Exp Clin Psychopharmacol. 2008;16(1):13–
• [PubMed] [Google Scholar]
• Minzenberg MJ, Carter CS. Modafinil: a review of neurochemical actions and effects on cognition. Neuropsychopharmacology. 2008;33(7):1477–1502. [PubMed] [Google Scholar]
• Ferraro L, Antonelli T, O’Connor WT, Tanganelli S, Rambert FA, Fuxe K. Modafinil: an anti narcoleptic drug with a different neurochemical profile to d-amphetamine and dopamine uptake blockers. Biol Psychiatry. 1997;42(12):1181–1183. [PubMed] [Google Scholar]
• Chemelli RM, Willie JT, Sinton CM, Elmquist JK, Scammell T, Lee C, et al. Narcolepsy in orexin knockout mice: molecular genetics of sleep regulation. Cell. 1999;98(4):437–451. [PubMed] [Google Scholar]
• Ohno K, Sakurai T. Orexin neuronal circuitry: role in regulating sleep and wakefulness. Front Neuroendocrinol. 2008;29(1):70–87. [PubMed] [Google Scholar]
• Willie JT, Renthal W, Chemelli RM, Miller MS, Scammell TE, Yanagisawa M, et al. Modafinil more effectively induces wakefulness in orexin-null mice than in wild-type littermates. Neuroscience. 2005;130(4):983–995. [PubMed] [Google Scholar]
• Lin JS, Hou Y, Jouvet M. Potential brain neuronal targets for amphetamine-, methylphenidate-, and modafinil-induced wakefulness, evidenced by c-fos immunocytochemistry in the cat. Proc Natl Acad Sci U S A. 1996;93(24):14128–14133. [PMC free article] [PubMed] [Google Scholar]
• Kumar R. Approved and investigational uses of Modafinil: an evidence-based review. Drugs. 2008;68(13):1803–1839. [PubMed] [Google Scholar]
• Duteil J, Rambert FA, Pessonnier J, Hermant JF, Gombert R, Assous E. Central alpha 1-adrenergic stimulation concerning Modafinil’s behavior stimulating effect with experimental animals. Eur J Pharmacol. 1990;180(1):49–58. [PubMed] [Google Scholar]
• Ferraro L, Antonelli T, O’Connor WT, Tanganelli S, Rambert FA, Fuxe K. The effects of Modafinil on striatal, pallidal, and nigral GABA and glutamate release in the conscious rat: evidence for a preferential inhibition of striatopallidal GABA transmission. Neurosci Lett. 1998;253(2):135–138. [PubMed] [Google Scholar]
• Ferraro L, Antonelli T, Tanganelli S, O’Connor WT, Perez de la Mora M, Mendez-Franco J, et al. The vigilance-promoting drug modafinil increases extracellular glutamate levels in the medial preoptic area and the posterior hypothalamus of the conscious rat: prevention by local GABAA receptor blockade. Neuropsychopharmacology. 1999;20(4):346–356. [PubMed] [Google Scholar]
• Ferraro L, Fuxe K, Tanganelli S, Fernandez M, Rambert FA, Antonelli T. Amplification of cortical serotonin release: a further neurochemical action of the vigilance-promoting drug modafinil. Neuropharmacology. 2000;39(11):1974–1983. [PubMed] [Google Scholar]
• Ishizuka T, Sakamoto Y, Sakurai T, Yamatodani A. Modafinil increases histamine release in the anterior hypothalamus of rats. Neurosci Lett. 2003;339(2):143–146. [PubMed] [Google Scholar]
• Ishizuka T, Murotani T, Yamatodani A. Modanifil activates the histaminergic system through the orexinergic neurons. Neurosci Lett. 2010;483(3):193–196. [PubMed] [Google Scholar]
• Simon P, Hémet C, Ramassamy C, Costentin J. Non-amphetaminic mechanism of the stimulant locomotor effect of Modafinil in mice. Eur Neuropsychopharmacol. 1995;5(4):509–514. [PubMed] [Google Scholar]
• Madras BK, Xie Z, Lin Z, Jassen A, Panas H, Lynch L, et al. Modafinil occupies dopamine and norepinephrine transporters in vivo and modulates the transporters and trace amine activity in vitro. J Pharmacol Exp Ther. 2006;319(2):561–569. [PubMed] [Google Scholar]
• Volkow ND, Fowler JS, Logan J, Alexoff D, Zhu W, Telang F, et al. Effects of Modafinil on dopamine and dopamine transporters in the male human brain: clinical implications. JAMA. 2009;301(11):1148–1154. [PMC free article] [PubMed] [Google Scholar]
• Nishino S, Mao J, Sampathkumaran R, Shelton J. Increased dopaminergic transmission mediates the wake-promoting effects of CNS stimulants. Sleep Res Online. 1998;1(1):49–61. [PubMed] [Google Scholar]
• Schmitt KC, Reith ME. The atypical stimulant and nootropic modafinil interact with the dopamine transporter differently from classical cocaine-like inhibitors. PLoS One. 2011;6(10):e25790. [PMC free article] [PubMed] [Google Scholar]
• Mignot E, Nishino S, Guilleminault C, Dement WC. Modafinil binds to the dopamine uptake carrier site with low affinity. Sleep. 1994;17(5):436–437. [PubMed] [Google Scholar]
• Zolkowska D, Jain R, Rothman RB, Partilla JS, Roth BL, Setola V, et al. Evidence for the involvement of dopamine transporters in behavioral stimulant effects modafinil. J Pharmacol Exp Ther. 2009;329(2):738–746. [PMC free article] [PubMed] [Google Scholar]
• De Saint Hilaire Z, Orosco M, Rouch C, Blanc G, Nicolaidis S. Variations in extracellular monoamines in the prefrontal cortex and medial hypothalamus after modafinil administration: a microdialysis study in rats. Neuroreport. 2001;12(16):3533–3537. [PubMed] [Google Scholar]
• Wisor JP, Nishino S, Sora I, Uhl GH, Mignot E, Edgar DM. Dopaminergic role in stimulant-induced wakefulness. J Neurosci. 2001;21(5):1787–1794. [PMC free article] [PubMed] [Google Scholar]
•  Murillo-Rodriguez E, Haro R, Palomero-Rivero M, Millan-Aldaco D, Drucker-Colin R. Modafinil enhances extracellular dopamine levels in the nucleus accumbens and increases wakefulness in rats. Behav Brain Res. 2007;176(2):353–357. [PubMed] [Google Scholar]
• Johnson RL, Block I, Gold MA, Markwell S, Zupancic M. Effect of methylphenidate on fatigue in women with recurrent gynecologic cancer. Psychooncology. 2010;19(9):955–958. [PubMed] [Google Scholar]
• Prommer E. Modafinil: is it ready for prime time? J Opioid Manag. 2006;2(3):130–136. [PubMed] [Google Scholar]
• Lange R, Volkmer M, Heesen C, Liepert J. Modafinil effects in multiple sclerosis patients with fatigue. J Neurol. 2009;256(4):645–650. [PubMed] [Google Scholar]
• Wesensten NJ, Belenky G, Kautz MA, Thorne DR, Reichardt RM, Balkin TJ. Maintaining alertness and performance during sleep deprivation: Modafinil versus caffeine. Psychopharmacology (Berl) 2002;159(3):238–247. [PubMed] [Google Scholar]
• Makris AP, Rush CR, Frederich RC, Taylor AC, Kelly TH. Behavioral and subjective effects of d-amphetamine and Modafinil in healthy adults. Exp Clin Psychopharmacol. 2007;15(2):123–133. [PubMed] [Google Scholar]
• McEwen BS. Physiology and neurobiology of stress and adaptation: central role of the brain. Physiol Rev. 2007;87(3):873–904. [PubMed] [Google Scholar]
• Lawrence DA, Kim D. Central/peripheral nervous system and immune responses. Toxicology. 2000;142(3):189–201. [PubMed] [Google Scholar]
• Chang FC, Opp MR. The corticotropin-releasing hormone (CRH) is a regulator of waking. Neurosci Biobehav Rev. 2001;25(5):445–453. [PubMed] [Google Scholar]
• Jacobs I, Bell DG. Effects of acute modafinil ingestion on exercise time to exhaustion. Med Sci Sports Exerc. 2004;36(6):1078–1082. [PubMed] [Google Scholar]
• Taneja I, Diedrich A, Black BK, Byrne DW, Paranjape SY, Robertson D. Modafinil elicits sympathomedullary activation. Hypertension. 2005;45(4):612–618. [PubMed] [Google Scholar]
• Roth T, Schwartz JR, Hirshkowitz M, Erman MK, Dayno JM, Arora S. Evaluation of the safety of Modafinil for the treatment of excessive sleepiness. J Clin Sleep Med. 2007;3(6):595–602. [PMC free article] [PubMed] [Google Scholar]
• Wesensten NJ. Effects of Modafinil on cognitive performance and alertness during sleep deprivation. Curr Pharm Des. 2006;12(20):2457–2471. [PubMed] [Google Scholar]

I’m a truck driver, so being awake and alert is part of my job. And that’s so easy with Modafinil. Herman. V. ⭐⭐⭐⭐⭐